白血病多药耐药与PTEN调控作用的研究进展

Research progress on multidrug resistance in leukemia and regulation of PTEN

逆转白血病的多药耐药是白血病治疗难点,研究表明PTEN基因作为一种具有蛋白磷酸酶及脂质磷酸酶双特性活性的抑癌基因,在白血病干细胞(LSCs)中低表达、突变或缺失,通过多种信号通路介导白血病细胞多药耐药,并参与细胞生长、分化、增殖。PTEN基因作为一种抑癌基因,有望为清除LSCs及逆转白血病多药耐药提供新的靶点。本文将从PTEN基因通过抑制MAPK信号通路、FAK/P130cas信号通路及负调控PI3K/AKt/mToR信号通路等参与调控细胞生长、分化、增殖,以及在白血病多药耐药中的研究进展作一综述。

Reversing multidrug resistance in leukemia is challenging. Studies have shown that PTEN gene is a tumor suppressor gene with protein phosphatase and lipid phosphatase activities. PTEN gene participates in cell growth, differentiation and proliferation through various signalling pathways and leukemia stem cells (LSCs) show mutation, deletion or reduction in expression of the PTEN gene. As such, PTEN gene is a potential target for clearing LSCs and reversing multidrug resistance in leukemia. This paper analyzes the regulatory activity of PTEN gene on cell growth, differentiation and proliferation through inhibiting the MAPK, FAK/P130cas and PI3K/AKt/mToR signalling pathways, also reviews the recent advancements in the research on the role of PTEN gene in multidrug resistance in leukemia.